IMARC Group has recently released a new research study titled "United States Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing and Region, 2026-2034", offering a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

United States Biologics Market Size & Share 2026-2034

The United States biologics market size reached USD 204.4 Billion in 2025 and is projected to reach USD 386.2 Billion by 2034, expanding at a CAGR of 7.11% during 2026-2034. In 2026, the market continues to gain momentum, propelled by the rapid adoption of advanced bioprocessing technologies, the expansion of biosimilars addressing affordability, and rising integration of artificial intelligence across drug discovery, clinical trials, and manufacturing.

Growth in 2026 is further reinforced by continued advances in biotechnology, sustained R&D investment by biotech and pharmaceutical firms, and supportive FDA frameworks that accelerate the introduction of new therapies. These dynamics are expected to strengthen the United States biologics market share throughout the forecast period.

Key Market Statistics at a Glance

• Base Year: 2025
• Historical Years: 2020-2025
• Forecast Period: 2026-2034
• Market Size (2025): USD 204.4 Billion
• Projected Market Size (2034): USD 386.2 Billion
• Growth Rate: CAGR of 7.11% (2026-2034)

Explore Opportunities in the United States Biologics Market: Download the IMARC Sample Report: https://www.imarcgroup.com/united-states-biologics-market/requestsample

Key Growth Drivers and Trends in the United States Biologics Market

Growth in the United States biologics market is being driven by the rapid adoption of advanced bioprocessing technologies, including single-use bioreactors, continuous manufacturing, and high-throughput screening systems that improve production efficiency and scalability while lowering costs. Rentschler Biopharma's Milford facility, operational since July 2024 with four 2,000L single-use bioreactors, doubled its cGMP capacity for complex biologics, reflecting the scale of investment in manufacturing upgrades to meet strong demand for monoclonal antibodies and gene therapies.

One of the leading United States biologics market trends is the rapid expansion of biosimilars, as patent expirations on branded biologics and the FDA's biosimilar approval pathway open the door to lower-cost alternatives. Biosimilars are improving access to treatment for chronic conditions such as cancer and autoimmune disorders, while increasing competition and easing cost pressure on patients and health systems.

Another key factor supporting United States biologics market growth is the rising burden of chronic disease. According to the CDC, an estimated 129 million Americans live with at least one chronic disease, and chronic conditions account for 90% of the country's annual USD 4.1 trillion in healthcare expenditure, underscoring the need for innovative biologic therapies. In parallel, the integration of AI is accelerating candidate identification, streamlining clinical trial recruitment and monitoring, and improving quality control and predictive maintenance in manufacturing.

Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=20441&flag=C

United States Biologics Industry Segmentation Insights

Breakup by Source:

• Microbial: Serves as an efficient, cost-effective host for recombinant proteins, enzymes, and vaccines, with E. coli and yeast systems offering high yield and scalability.
• Mammalian: Critical for complex biologics such as monoclonal antibodies, fusion proteins, and cell therapies, with CHO cells dominating thanks to superior post-translational modifications.
• Others: Includes additional expression platforms supporting specialized and emerging biologic modalities.

Breakup by Product:

• Monoclonal Antibodies: A mainstay of the market, widely used in cancer, autoimmune diseases, and infections, with antibody-drug conjugates and bispecific antibodies driving innovation.
• Vaccines: Growing at a strong pace, supported by advances in mRNA technology, pandemic preparedness, and rising immunization initiatives.
• Recombinant Proteins: Widely used in treating diabetes, anemia, and growth disorders, with protein engineering and biosimilars improving efficacy and affordability.
• Antisense, RNAi and Molecular Therapy: Addresses genetically defined diseases through targeted molecular approaches.
• Others: Includes additional biologic product categories serving diverse therapeutic needs.

Breakup by Disease:

• Oncology: Leads the market, supported by the high cancer burden and the shift toward targeted treatments such as checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapy.
• Immunological Disorders: Shows strong growth with rising cases of rheumatoid arthritis, psoriasis, and inflammatory bowel disease, while biosimilars widen access.
• Cardiovascular Disorders: Gaining ground through therapies such as PCSK9 inhibitors and growing investment in regenerative and rare cardiovascular biologics.
• Hematological Disorders: Supported by ongoing development of biologic and cell-based therapies for blood-related conditions.
• Others: Covers additional disease areas where biologics are expanding clinical use.

Breakup by Manufacturing:

• Outsourced: Expanding as companies rely on CROs and CMOs for cost-efficient production, scalable facilities, and regulatory support, particularly for biosimilars and gene therapies.
• In-House: Remains vital for companies prioritizing control over quality, processes, and intellectual property, with large pharma investing in advanced facilities.

Breakup by Region:

• Northeast: Driven by a dense cluster of biotech and pharmaceutical companies in Massachusetts and New York, backed by academic institutions and a skilled workforce.
• Midwest: Growing rapidly in biologics manufacturing, with Illinois and Indiana contributing production capabilities and university-industry collaboration.
• South: Benefits from a favorable business climate in states such as North Carolina and Texas, rising clinical trial activity, and expanding life sciences investment.
• West: Leads innovation, particularly in California, with strength in CAR-T therapies, mRNA vaccines, personalized medicine, and strong venture capital funding.

Key Challenges and Growth Opportunities in the United States Biologics Market

The United States biologics market faces challenges including the high cost and complexity of building and operating advanced manufacturing facilities, and the need to maintain consistent quality and regulatory compliance as new modalities such as cell and gene therapies scale. Pricing pressure from biosimilar competition and patent-related disputes also shapes the strategies of originator companies.

Despite these challenges, the market offers considerable growth opportunities driven by the rising prevalence of chronic diseases, expanding healthcare expenditure and favorable reimbursement policies, and the shift toward personalized medicine. Continued investment in bioprocessing capacity, AI-enabled development, and next-generation therapies is expected to create substantial long-term opportunities.

Competitive Landscape

The United States biologics market is competitive, with leading pharmaceutical and biotechnology innovators investing heavily in R&D to advance portfolios of next-generation monoclonal antibodies, vaccines, and gene therapies. Emerging startups, contract research organizations, and contract manufacturers add niche products and outsourcing solutions, while strategic partnerships, acquisitions, and advances in manufacturing and personalized medicine continue to reshape the competitive environment.

Recent Developments in the United States Biologics Market

• September 2024: The FDA approved Dupixent (dupilumab) as the first biologic for inadequately controlled COPD with an eosinophilic phenotype, with Phase 3 trials showing reduced exacerbations and improved lung function.
• May 2024: Galapagos NV and Blood Centers of America partnered to decentralize CAR-T therapy manufacturing across 50 U.S. centers, targeting seven-day vein-to-vein delivery.
• February 2024: Biocon Biologics signed a settlement and license agreement with Janssen Biotech to commercialize Bmab 1200, a biosimilar to Stelara (ustekinumab), in the U.S. starting February 2025, pending FDA approval.

Author IMARC Group

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multidisciplinary team of industry experts, IMARC delivers reliable market intelligence across sectors including Chemicals and Materials, Healthcare, Technology, Agriculture, and Retail.

Contact Us:

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201-971-6302